216 related articles for article (PubMed ID: 27466197)
1. Pridopidine activates neuroprotective pathways impaired in Huntington Disease.
Geva M; Kusko R; Soares H; Fowler KD; Birnberg T; Barash S; -Wagner AM; Fine T; Lysaght A; Weiner B; Cha Y; Kolitz S; Towfic F; Orbach A; Laufer R; Zeskind B; Grossman I; Hayden MR
Hum Mol Genet; 2016 Sep; 25(18):3975-3987. PubMed ID: 27466197
[TBL] [Abstract][Full Text] [Related]
2. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
Kusko R; Dreymann J; Ross J; Cha Y; Escalante-Chong R; Garcia-Miralles M; Tan LJ; Burczynski ME; Zeskind B; Laifenfeld D; Pouladi M; Geva M; Grossman I; Hayden MR
Mol Neurodegener; 2018 May; 13(1):25. PubMed ID: 29783994
[TBL] [Abstract][Full Text] [Related]
3. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.
Ryskamp D; Wu J; Geva M; Kusko R; Grossman I; Hayden M; Bezprozvanny I
Neurobiol Dis; 2017 Jan; 97(Pt A):46-59. PubMed ID: 27818324
[TBL] [Abstract][Full Text] [Related]
4. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.
Squitieri F; Di Pardo A; Favellato M; Amico E; Maglione V; Frati L
J Cell Mol Med; 2015 Nov; 19(11):2540-8. PubMed ID: 26094900
[TBL] [Abstract][Full Text] [Related]
5. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.
Garcia-Miralles M; Geva M; Tan JY; Yusof NABM; Cha Y; Kusko R; Tan LJ; Xu X; Grossman I; Orbach A; Hayden MR; Pouladi MA
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212949
[TBL] [Abstract][Full Text] [Related]
6. Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.
Waters S; Tedroff J; Ponten H; Klamer D; Sonesson C; Waters N
J Huntingtons Dis; 2018; 7(1):1-16. PubMed ID: 29480206
[TBL] [Abstract][Full Text] [Related]
7. Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [
Grachev ID; Meyer PM; Becker GA; Bronzel M; Marsteller D; Pastino G; Voges O; Rabinovich L; Knebel H; Zientek F; Rullmann M; Sattler B; Patt M; Gerhards T; Strauss M; Kluge A; Brust P; Savola JM; Gordon MF; Geva M; Hesse S; Barthel H; Hayden MR; Sabri O
Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1103-1115. PubMed ID: 32995944
[TBL] [Abstract][Full Text] [Related]
8. Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.
Squitieri F; de Yebenes JG
Drug Des Devel Ther; 2015; 9():5827-33. PubMed ID: 26604684
[TBL] [Abstract][Full Text] [Related]
9. Pridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model.
Lenoir S; Lahaye RA; Vitet H; Scaramuzzino C; Virlogeux A; Capellano L; Genoux A; Gershoni-Emek N; Geva M; Hayden MR; Saudou F
Neurobiol Dis; 2022 Oct; 173():105857. PubMed ID: 36075537
[TBL] [Abstract][Full Text] [Related]
10. The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models.
Naia L; Ly P; Mota SI; Lopes C; Maranga C; Coelho P; Gershoni-Emek N; Ankarcrona M; Geva M; Hayden MR; Rego AC
Neurotherapeutics; 2021 Apr; 18(2):1017-1038. PubMed ID: 33797036
[TBL] [Abstract][Full Text] [Related]
11. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.
Eddings CR; Arbez N; Akimov S; Geva M; Hayden MR; Ross CA
Neurobiol Dis; 2019 Sep; 129():118-129. PubMed ID: 31108174
[TBL] [Abstract][Full Text] [Related]
12. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor.
Ryskamp D; Wu L; Wu J; Kim D; Rammes G; Geva M; Hayden M; Bezprozvanny I
Neurobiol Dis; 2019 Apr; 124():489-504. PubMed ID: 30594810
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of the Dopaminergic Stabilizer Pridopidine and Tetrabenazine in Rats.
Waters S; Ponten H; Klamer D; Waters N
J Huntingtons Dis; 2014; 3(3):285-98. PubMed ID: 25300332
[TBL] [Abstract][Full Text] [Related]
14. The p75 neurotrophin receptor augments survival signaling in the striatum of pre-symptomatic Q175(WT/HD) mice.
Wehner AB; Milen AM; Albin RL; Pierchala BA
Neuroscience; 2016 Jun; 324():297-306. PubMed ID: 26947127
[TBL] [Abstract][Full Text] [Related]
15. Pridopidine for the treatment of Huntington's disease.
Shannon KM
Expert Opin Investig Drugs; 2016; 25(4):485-92. PubMed ID: 26881734
[TBL] [Abstract][Full Text] [Related]
16. Pridopidine reduces mutant huntingtin-induced endoplasmic reticulum stress by modulation of the Sigma-1 receptor.
Shenkman M; Geva M; Gershoni-Emek N; Hayden MR; Lederkremer GZ
J Neurochem; 2021 Jul; 158(2):467-481. PubMed ID: 33871049
[TBL] [Abstract][Full Text] [Related]
17. Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.
McGarry A; Auinger P; Kieburtz K; Geva M; Mehra M; Abler V; Grachev ID; Gordon MF; Savola JM; Gandhi S; Papapetropoulos S; Hayden M
J Huntingtons Dis; 2020; 9(2):173-184. PubMed ID: 32508327
[TBL] [Abstract][Full Text] [Related]
18. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
[TBL] [Abstract][Full Text] [Related]
19. Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose.
Darpo B; Geva M; Ferber G; Goldberg YP; Cruz-Herranz A; Mehra M; Kovacs R; Hayden MR
Neurol Ther; 2023 Apr; 12(2):597-617. PubMed ID: 36811812
[TBL] [Abstract][Full Text] [Related]
20. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
Ma Q; Yang J; Li T; Milner TA; Hempstead BL
Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
